Market Newsdesk

Forward Air Corporation Announces Expanded LTL Service Offering in Bethlehem, PA

GREENEVILLE, Tenn.–(BUSINESS WIRE)–
Forward Air Corporation (NASDAQ: FWRD) (the “Company” or “Forward”) is executing a growth strategy that involves organic infrastructure investments such as the ongoing LTL network expansion, as well as inorganic investments, including acquisitions of complementary businesses. Today, Forward announced that it will expand its expedited less-than-truckload (LTL) service in Bethlehem, Pa.

Forward selected Bethlehem based on prior success with its LTL business using a local partner. Forward secured a new location in Bethlehem, where it will open a Company-operated facility – a move that signals Forward’s growth trajectory into cities that are not adjacent to major airports.

Tom Schmitt, Chairman, President and Chief Executive Officer said, “As we continue to expand our service offering beyond our current airport-to-airport footprint, Bethlehem is a strategic location that supports future growth. At the same time, we can support our Philadelphia operations and increase our coverage in Pennsylvania.”

With the addition of a Forward-operated terminal, the Bethlehem market is now connected to Forward’s nationwide network and portfolio of premium freight management services in LTL, full truckload, intermodal drayage and final mile delivery.

About Forward Air Corporation

Forward Air Corporation (NASDAQ: FWRD) is a leading asset-light freight and logistics company. We provide LTL, final mile, truckload, intermodal drayage and pool distribution services across the United States and in Canada. Headquartered in Greeneville, Tennessee, Forward operates approximately 200 facilities across the country and employs more than 5,200 people nationwide. We are more than a transportation company. As a single resource for your shipping needs, Forward is your supply chain partner. For more information, visit our website at www.forwardaircorp.com.

This press release may contain statements that might be considered as forward-looking statements or predictions of future operations including with respect to the expected growth and future expansion of the Company’s network and footprint. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation of information currently available. These statements and assumptions involve certain risks and uncertainties including that the performance of the LTL service in Bethlehem is worse than anticipated and that the Company is not able to achieve its planned expansion. Actual events may also differ from these expectations as a result of the risks identified from time to time in our filings with the Securities and Exchange Commission. You should consider the forward-looking statement contained herein in light of such risks. We assume no duty to update these statements as of any future date.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005384/en/

Justin Moss

[email protected]

404-362-2472.

KEYWORDS: United States North America Pennsylvania Tennessee

INDUSTRY KEYWORDS: Trucking Transport Logistics/Supply Chain Management Other Transport

MEDIA:

Logo

The Royal Berkshire NHS Foundation Trust Looks to Future of Healthcare with Citrix®

Medical services provider leverages digital workspace solutions to create exceptional experience for clinicians, support safer patient care

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–
The future of healthcare is digital. And with the help of Citrix Systems, Inc. (NASDAQ:CTXS), The Royal Berkshire NHS Foundation Trust (RBFT) is working to deliver it today.

“At RBFT, our legacy is one of innovation and change and we are always looking ahead to the challenges of the future and how we can apply technology to overcome them and enhance the health and wellbeing of the people we serve,” said Heather Allan, Director of IM&T, RBFT.

And it is working in partnership with Citrix to achieve this goal.

“We need to make information available quickly, wherever it’s required, while always ensuring that patient data is protected,” Allan said. “And we need IT to be an enabler and not a blocker that causes delay in patient care.”

Creating the Space to Succeed

With support from Platinum Citrix Solution Advisor Ultima, RBFT has implemented Citrix Virtual Apps and Desktops™, which it is using to do just this. Using Citrix Virtual Apps and Desktops, RBFT can provide secure and reliable access to the systems and applications its clinicians need, when and where they need them, and deliver a consistent experience that eliminates the distractions technology can create so they can focus and do what they do best: deliver high quality care.

“User experience is very important,” Allan added. “And consistency is key. Clinicians expect their IT environments to be the same wherever they log in, because they have no time to worry about which applications are available on a particular machine, or what order the icons appear in. And they definitely don’t have time to call IT support.”

With Citrix, RBFT can enable faster decision making among its clinicians. And according to David Clarke, Emergency Department Consultant, RBFT, this leads to improved patient care and better outcomes.

“In the emergency department, everything moves so quickly. You only have a limited amount of time per patient and anything you can do to make that more efficient allows you to see more patients and to spend more time with each patient. It’s a better, more efficient use of doctors’ precious time,” he said.

Securing Data and Devices

For healthcare organizations managing sensitive data, security is critical. And Citrix delivers on this front as well, providing a single pane through which IT can dynamically manage security and quickly and easily apply patches, updates and policies on all endpoints to maintain the safety of its systems and data.

“It’s a 21st century platform which gives medical staff consolidated authentication through tap and go, and it saves considerable time in time-critical situations like drug dispensing,” Allan said. “You don’t want patients waiting for, say, morphine, while a doctor and his co-authorizing peer have their successive logins authenticated to dispense the drug. With Citrix, it’s seamless.”

RBFT joins dozens of leading healthcare organizations – including the 10 largest in the United States – who are using Citrix solutions to transform patient care. Click here to learn more about these solutions and the value the are delivering.

About The Royal Berkshire NHS Foundation Trust

The Royal Berkshire NHS Foundation Trust is one of the largest district general hospital foundation trusts in the UK. We provide acute medical and surgical services to Reading, Wokingham and West Berkshire and specialist services such as cancer, dialysis and eye surgery to a wider population across Berkshire and its borders. To learn more about the Trust, visit https://www.royalberkshire.nhs.uk/

About Citrix

Citrix (NASDAQ: CTXS) builds the secure, unified digital workspace technology that helps organizations unlock human potential and deliver a consistent workspace experience wherever work needs to get done. With Citrix, users get a seamless work experience and IT has a unified platform to secure, manage, and monitor diverse technologies in complex cloud environments.

For Citrix Investors:

This release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and of Section 21E of the Securities Exchange Act of 1934. The forward-looking statements in this release do not constitute guarantees of future performance. Those statements involve a number of factors that could cause actual results to differ materially, including risks associated with the impact of the global economy and uncertainty in the IT spending environment, revenue growth and recognition of revenue, products and services, their development and distribution, product demand and pipeline, economic and competitive factors, the Company’s key strategic relationships, acquisition and related integration risks as well as other risks detailed in the Company’s filings with the Securities and Exchange Commission. Citrix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein. The development, release and timing of any features or functionality described for our products remains at our sole discretion and is subject to change without notice or consultation. The information provided is for informational purposes only and is not a commitment, promise or legal obligation to deliver any material, code or functionality and should not be relied upon in making purchasing decisions or incorporated into any contract.

© 2020 Citrix Systems, Inc. Citrix, the Citrix logo, and other marks appearing herein are the property of Citrix Systems, Inc. and may be registered with the U.S. Patent and Trademark Office and in other countries. All other marks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005343/en/

Karen Master

Citrix

+1 216-396-4683

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Software Practice Management General Health Health Data Management Hospitals Technology Security

MEDIA:

Logo

8×8 Named a Leader in 2020 Gartner Magic Quadrant for Unified Communications as a Service, Worldwide

8×8 Recognized as a Leader for the Ninth Year in a Row

CAMPBELL, Calif.–(BUSINESS WIRE)–8×8, Inc. (NYSE: EGHT), a leading integrated cloud communications platform, today announced it has been named a Leader in the 2020 Gartner Magic Quadrant for Unified Communications as a Service, Worldwide¹. This is the ninth consecutive year 8×8 has been recognized as a Leader in this report.

“Global enterprises have become heavily reliant on their providers to deliver all the key communications and collaboration capabilities required to keep employees, partners and customers connected from anywhere on any device,” said Vik Verma, Chief Executive Officer at 8×8, Inc. “We are honored to be recognized for the ninth year in a row as a Magic Quadrant Leader. We believe it demonstrates that our ongoing investments in our go-to-market strategy and single-vendor open communications platform are paying off. Organizations are choosing 8×8 to support a new operate-from-anywhere imperative, ensuring employees have the tools they need to work productively within teams, across offices, and around the world.”

8×8 X Series transforms customer and employee experiences with a single, integrated solution for voice, meetings, team chat, contact center and Communications Platform as a Service (CPaaS) enterprise APIs, and all powered by the 8×8 Open Communications Platform. 8×8 X Series helps organizations to rapidly unify a distributed workforce, with fluid and seamless communications that enables workers to move from a group chat to a private conversation, or from a call to a video meeting with screen sharing at the click of a button using the 8×8 Work desktop or mobile apps. In addition, 8×8 Voice for Microsoft Teams allows Microsoft Teams users to make and receive calls on the public phone network right from the native Teams app using direct routing from 8×8.

In addition to being named a Leader in the Gartner Magic Quadrant for Unified Communications as a Service, Worldwide, 8×8 was also recently recognized as a Challenger in the Gartner Magic Quadrant for Contact Center as a Service².

[1] Gartner Magic Quadrant for Unified Communications as a Service, Worldwide, Rafael Benitez, Megan Fernandez, Daniel O’Connell, Christopher Trueman, Pankil Sheith, November 12, 2020. This Magic Quadrant report name has changed from 2015 onwards- 2015-2020: Magic Quadrant for Unified Communications as a Service, Worldwide, 2014: Magic Quadrant for Unified Communications as a Service, North America With Additional Regional Presence, 2012-2013: Magic Quadrant for Unified Communications as a Service, North America.

[2] Gartner Magic Quadrant for Contact Center as a Service, Steve Blood, Drew Kraus, Pri Rathnayake, November 9, 2020.

Gartner Disclaimer:

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

About 8×8, Inc.

8×8, Inc. (NYSE: EGHT) is transforming the future of business communications as a leading Software-as-a-Service provider of voice, video, chat, contact center, and enterprise-class API solutions powered by one global cloud communications platform. 8×8 empowers workforces worldwide to connect individuals and teams so they can collaborate faster and work smarter. Real-time business analytics and intelligence provide businesses unique insights across all interactions and channels so they can delight end-customers and accelerate their business. For additional information, visit www.8×8.com, or follow 8×8 on LinkedIn, Twitter and Facebook.

8×8® and 8×8 X Series™ are trademarks of 8×8, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005392/en/

8×8, Inc. Contacts:

Media:

John Sun, 1-408-692-7054

john.sun@8×8.com

Investor Relations:

Victoria Hyde-Dunn, 1-669-333-5200

victoria.hyde-dunn@8×8.com

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology VoIP Telecommunications

MEDIA:

Logo

Pioneer Floating Rate Trust Announces Commencement of Tender Offer

BOSTON–(BUSINESS WIRE)–
Pioneer Floating Rate Trust (NYSE: PHD) (the “Fund”) announced today that it has commenced a tender offer. The Fund will purchase up to 50% of the Fund’s outstanding common shares (the “Shares”) at a price per Share equal to 98.5% of the net asset value per Share as of the close of regular trading on the New York Stock Exchange (“NYSE”) on the business day immediately following the expiration date of the tender offer. The tender offer will expire on December 22, 2020 at 5:00 p.m. Eastern Standard Time, unless the offer is extended by the Fund in its sole discretion. The Fund previously announced its intention to conduct the tender offer in a press release dated August 31, 2020.

Additional terms and conditions of the tender offer are set forth in the Fund’s tender offer materials, which are being distributed to holders of Shares. The Fund will repurchase Shares tendered and accepted in the tender offer in exchange for cash. In the event more than 50% of the Shares are tendered, and not withdrawn, the Fund will purchase Shares from tendering shareholders on a pro rata basis. Accordingly, shareholders cannot be assured that the Fund will purchase all of a shareholder’s tendered Shares.

Tender Offer Statement

This announcement is not a recommendation, an offer to purchase or a solicitation of an offer to sell shares of the Fund and the above statements are not intended to constitute an offer to participate in any tender offer. The tender offer will be made only by an offer to purchase, a related letter of transmittal, and other documents, to be filed with the Securities and Exchange Commission (the “SEC”) as exhibits to the tender offer statement on Schedule TO. Shareholders of the Fund should read the offer to purchase and tender offer statement on Schedule TO and related exhibits, as they will contain important information about the tender offer. These and other filed documents will be available to investors free of charge both on the SEC’s website, http://www.sec.gov, and from the Fund, by calling AST Fund Solutions, LLC, the Fund’s information agent for the tender offer, at (877) 478-5039 (toll-free).

About Pioneer Floating Rate Trust

The Fund is a closed-end investment company traded on the NYSE under the symbol PHD. The Fund seeks a high level of current income. The Fund also seeks capital preservation as a secondary objective to the extent consistent with its primary objective.

About Amundi Pioneer Asset Management

Amundi Pioneer is the U.S. business of Amundi, Europe’s largest asset manager by assets under management and ranked among the ten largest globally[1]. Boston is one of Amundi’s six main global investment hubs and offers a broad range of fixed-income, equity, and multi-asset investment solutions in close partnership with wealth management firms, distribution platforms, and institutional investors across the Americas, Europe, and Asia-Pacific. Our long history of proprietary research, robust risk management, disciplined investment processes, and strong client relationships has made Amundi Pioneer an investment advisor of choice among leading institutional and individual investors worldwide. Amundi Pioneer had approximately $89 billion in assets under management as of September 30, 2020.

^[1] Source IPE “Top 500 asset managers” published in June 2020 and based on AUM as of end December 2019.

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain statements regarding plans and expectations for the future that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”), and such statements are intended to qualify for the safe harbors from liability established by the PSLRA. All statements other than statements of historical fact are forward-looking and can sometimes be identified as such by the context of the statements, including words such as “believe,” “could,” “expect,” “anticipate,” “plan,” “may,” “will,” “would,” “should,” “intend,” “possible,” “continue” “project,” “estimate,” “guidance” and other similar terms and phrases, whether in the negative or affirmative, although not all forward-looking statements include these words. Similarly, statements that describe the objectives, plans, or goals of the Fund or its investment adviser are forward-looking. Such forward-looking statements are based upon the Fund’s current plans, estimates and expectations and are not a representation that such plans, estimates, or expectations will be achieved. Because such statements include risks, uncertainties and contingencies, actual events may differ materially from the expectations, intentions, beliefs, plans or predictions of the future expressed or implied by such forward-looking statements. Additionally, past performance is no guarantee of future results. Additional information concerning such risks and uncertainties are or will be contained in the Fund’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including the Fund’s Annual Report to Shareholders on Form N-CSR for the fiscal year ended November 30, 2019, and its subsequent filings with the SEC which are available at http://www.sec.gov. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. Except as required by applicable law, the Fund undertakes no obligation to update publicly these statements for any reason, whether to reflect new information or the occurrence of unanticipated events or otherwise, following the date of this press release.

Visit amundipioneer.com/us for more information.

Follow us on www.linkedin.com/company/amundi-pioneer and https://twitter.com/amundipioneer.

Amundi Pioneer Distributor, Inc., Member SIPC

©2020 Amundi Pioneer Asset Management

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005277/en/

Shareholder Inquiries: Please contact your financial advisor or visit amundipioneer.com/us.

Broker/Advisor Inquiries Please Contact: 800-622-9876

Media Inquiries Please Contact: Geoff Smith, 617-422-4758

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Professional Services Finance

MEDIA:

Logo

Nautilus, Inc. to Participate in Upcoming Virtual Investor Conferences

VANCOUVER, Wash.–(BUSINESS WIRE)–
Nautilus, Inc. (the “Company”) (NYSE: NLS) today announced that management will participate in the following virtual investor conferences:

Truist Securities 2020 Gaming, Lodging, Leisure & Restaurants Summit

Management will participate in virtual one-on-one and small group meetings on Thursday, December 10, 2020. There will be no formal presentation.

ROTH Virtual Deer Valley Consumer Event

Management will speak on the “Understanding Fitness – COVID and Beyond!” panel on Thursday, December 10, 2020, at 1:30PM PT and participate in virtual one-on-one and small group meetings on Friday, December 11, 2020.

William Blair FutureView 2020: The Consumer

Management will participate in “Future of Fitness” panel on Tuesday, December 15, 2020, at 8:00AM PT. There will be no formal presentation or one-on-one meetings.

About Nautilus, Inc.

Headquartered in Vancouver, Washington, Nautilus, Inc. (NYSE: NLS) is a global technology driven fitness solutions company that believes everyone deserves a fit and healthy life. With a brand portfolio including Bowflex®, Nautilus®, Schwinn® and JRNY™. Nautilus, Inc. develops innovative products to support healthy living through direct and retail channels. Nautilus, Inc. uses the investor relations page of its website (www.nautilusinc.com/investors) to make information available to its investors and the market.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201123005212/en/

Investor Relations:

John Mills

ICR, LLC

646-277-1254

[email protected]

Media:

John Fread

Nautilus, Inc.

360-859-5815

[email protected]

Carey Kerns

The Hoffman Agency

503-754-7975

[email protected]

KEYWORDS: United States North America Washington

INDUSTRY KEYWORDS: Other Retail Vacation Specialty Other Consumer Fitness & Nutrition Women Other Sports Retail Other Professional Services Men Health Mobile Entertainment Finance Banking Consumer Professional Services General Sports Other Entertainment Other Travel General Entertainment Lodging Casino/Gaming Travel Entertainment Other Health General Health Restaurant/Bar Sports

MEDIA:

Posted on November 23, 2020 8:33 am

Premier Health Announces the Appointment of Sylvain Charbonneau as its New CFO

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) — Premier Health of America Inc. (formerly known as Physinorth Acquisition Corporation Inc.) (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian Healthtech company, today announced the appointment of Sylvain Charbonneau to serve as Chief Financial Officer of the Company, effective November 23, 2020.

“We are very excited to have Sylvain Charbonneau join Premier Health. He will be a close advisor to me and an important member of the Corporation’s senior leadership team as we continue to expand and execute our growth strategy,” said Martin Legault, Chief Executive Officer. “We are confident that his leadership, finance and accounting experience will benefit Premier Health and its shareholders. I look forward to developing a close and productive working relationship with Sylvain,” he added.

Over the past 10 years, Mr. Charbonneau has held the position of Chief Financial Officer in manufacturing companies operating internationally, including Transtex / E-Smart Control since 2016. From 2005 to 2010, Mr. Charbonneau was part of the Corporate Finance team at Deloitte in Montreal as Vice-President where he carried out several M&A transactions as well as several large financings. From 1997 to 2005, he was a partner in a consulting firm where he worked on several large international investment projects, including phase 2 of the Alouette aluminum smelter, as well as several other projects in the fine chemicals, petrochemicals, aluminum processing, distributed power generation and various other high value-added sectors. He holds a bachelor’s degree in finance from the University of Sherbrooke and an MBA from the University of Montreal (HEC).
        
Mr. Charbonneau is replacing Joseph Cianci who will continue acting as a board member and will be involved in the transition ahead. The board of directors takes this opportunity to thank Mr. Cianci for his long involvement with the Corporation and his key role in the recent qualifying transaction.

About Premier Health
,

Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of staffing and outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary PSweb platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper and more accessible care services.

For Further Information Please Contact:

Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
(formerly known as Physinorth Acquisition Corporation Inc.)
[email protected] / 514-581-1473

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Corporation’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of
the Corporation
with Canadian securities regulatory authorities available at www.sedar.com.

Posted on November 23, 2020 8:33 am

AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation

• Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not
• AB201 is the only novel compound being developed for COVID Associated Coagulopathy
• Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December
• Topline trial data anticipated Q2 2021

WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of AB201 as a potential treatment for COVID-19. The Company intends to initiate a Phase 2b clinical trial (ASPEN-COVID-19) of AB201 in approximately 100 patients hospitalized with COVID-19 in December 2020, with topline trial data anticipated in the second quarter of 2021.

According to the FDA’s Fast Track Guidance document, Fast Track programs are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.

“Fast Track designation for the AB201 development program is an important acknowledgement of the critical need for treatments for hospitalized COVID-19 patients, whether effective vaccines are approved and available or not,” said Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, who is also an American Heart Association (AHA) funded COVID-19 investigator. “We believe AB201’s combination of anticoagulant, anti-inflammatory and antiviral effects may favorably impact clinical recovery of patients hospitalized with COVID-19 and look forward to beginning the ASPEN-COVID-19 trial to evaluate AB201’s potential efficacy in this patient population.”

Fast Track drug development designation is included in the FDA Modernization Act of 1997 (FDAMA) as a formal process to enhance interactions with the FDA during drug development. A drug development program with Fast Track designation would be eligible for consideration for some or all of the following programs for expediting development and review: scheduled meetings to seek FDA input into development plans, priority review of the New Drug Application (NDA), the option of submitting portions of an NDA prior to submission of the complete application and potential accelerated approval. ARCA believes that AB201 is the only anticoagulant class new chemical entity in development for COVID-19 that has a Fast Track designation.

About
AB201

AB201 is a small recombinant protein being developed as a potential treatment for RNA virus-associated diseases, initially focusing on COVID-19. AB201 is a potent, selective inhibitor of tissue factor (TF), which has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. Its unique mechanism of action gives AB201 a combination of anticoagulant, anti-inflammatory and antiviral properties, and therefore the potential to be effective in addressing the impact of viral infections from multiple pathways. AB201 has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including in clinical studies for prevention of venous and arterial thrombosis, where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other severe infections in which the infection process causes inappropriate activation of the coagulation system and other aspects of the immune response, resulting in serious complications. Recent mechanistic discoveries, as well as prior data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating morbidity and mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that AB201 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. The Company believes that collectively these observations provide a strong rationale for investigating AB201 as a treatment for COVID-19 and other RNA virus associated diseases.

About ARCA biopharma

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing Gencaro^TM (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential pharmacogenetic treatment for atrial fibrillation in patients with heart failure. For more information, please visit www.arcabio.com or follow the Company on LinkedIn.

Safe Harbor Statement

This press release contains “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding
potential
future
development plans for
AB201
, the
expected features and characteristics of
AB201
,
AB201’
s potential to treat
COVID-19
, CAC
or
any other RNA virus associated disease
,
whether AB201
is the only anticoagulant class new chemical entity in development for COVID-19 that has a Fast Track designation
and
future treatment options for patients with
COVID-19
.
Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s financial resources and whether they will be sufficient to meet its business objectives and operational requirements;
ARCA
may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of
AB201
or t
o otherwise continue operations in the future;
results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and
described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on Form 10-K for the year ended
December
 
31
,
 
201
9
, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.

Investor & Media Contact:

Derek Cole
720.940.2163
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/af496e97-20da-420a-bf93-e51b3a3ed740 

Posted on November 23, 2020 8:33 am

Nabis Holdings Inc. Announces Recapitalization Transaction With Support of Key Stakeholders

VANCOUVER, British Columbia, Nov. 23, 2020 (GLOBE NEWSWIRE) — Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: A2PL) (“Nabis” or the “Company”) today announced that it has entered into a support agreement (the “Support Agreement”) with certain holders (“Debentureholders”) of the Company’s outstanding $35 million principal amount 8.0% unsecured convertible debentures (the “Debentures”). Pursuant to the Support Agreement, the Debentureholders party thereto have agreed to support a recapitalization plan for Nabis that will, subject to required approval of Nabis’ creditors (the “Creditors”) and the Ontario Superior Court of Justice, result in the recapitalization of the Debentures and all other debts of the Company (the “Recapitalization”). The Recapitalization is to be implemented pursuant to a proposal (the “Proposal”) under the Bankruptcy and Insolvency Act of Canada (the “BIA”). The Proposal will be filed with the Official Receiver imminently.   

The material terms of the Proposal are:

(i)  the cancellation of all of the common shares, preferred shares, warrants, stock options and any other similar equity-type securities in the capital of the Company (collectively, “Equity Claims”);

(ii)  all Equity Claims will be irrevocably and finally extinguished upon implementation of the Proposal;

(iii)  in full and final satisfaction of all Creditor claims, which will be irrevocably and finally extinguished, on the implementation date of the Proposal, Nabis shall issue and pay to each Creditor its pro rata share of:

    (a)  3,700,000 new common shares in the capital of the Company; and

    (b)  new 5.3% first lien notes in the aggregate amount of $23 million due 2022 on the terms set out in the Proposal; and

(iv)  certain persons, including the Company and each of its affiliates and the Debentureholders party to the Support Agreement, and each of their respective former and current officers, directors, principals and employees, will receive releases of certain claims pursuant to the BIA.

KSV Restructuring Inc. will act as proposal trustee pursuant to the BIA in respect of the Proposal (in such capacity, the “Proposal Trustee“).

Under the Support Agreement, the Debentureholders party thereto have agreed, subject to certain conditions precedent and termination rights, to support and vote for the Proposal at the meeting of the Creditors to be held on December 14, 2020 (the “Creditors’ Meeting”). Under the terms of the Support Agreement, Nabis has agreed to certain customary covenants and restrictions with respect to its business and operations until the Proposal has been implemented.

The Creditors’ Meeting and Voting Matters

The Creditors’ Meeting is scheduled to be held virtually on December 14, 2020, and is scheduled to begin at 10:00 a.m. (Toronto time). Due to the COVID-19 pandemic, the Creditors’ Meeting will be held online at the following website: https://us02web.zoom.us/j/82452022771?pwd=UUFPaUFqV1o1a0sxc0thWVl4SVNtZz09.

The record date for determining the amount of each Creditor’s claim is 5:00 p.m. (Toronto time) on December 7, 2020.

In order to vote on the Proposal, Debentureholders are required to submit a proxy and voting letter to the Proposal Trustee by no later than 5:00 p.m. (Toronto time) on December 11, 2020. Holders or custodians (“Participant Holders“) of Debentures on behalf of beneficial Debentureholders will be provided with Proposal materials, and are asked to complete and sign the applicable part of the voting and proxy letter for Debentureholders and to transmit it along with the other Proposal materials to each applicable beneficial Debentureholder. Beneficial Debentureholders are encouraged to contact their Participant Holders directly to confirm any voting requirements.

Alternatively, beneficial Debentureholders may access and download the proxy and voting letter directly from the Proposal Trustee at www.ksvadvisory.com/insolvency-cases/case/nabis-holdings (the “Proposal Trustee’s Website“). Additional information relating to the Creditors’ Meeting and Proposal process will be posted to the Proposal Trustee’s Website later today.

Affected Creditors who are not Debentureholders that wish to attend the Creditors’ Meeting and vote on the Proposal must submit a proof of claim to the Proposal Trustee by no later than 5:00 p.m. (Toronto time) on December 11, 2020.

Affected Creditors who are not Debentureholders and who have claims in an amount greater than $500.00 may elect to be treated for all purposes under the Proposal as Convenience Creditors (as defined in the Proposal) by submitting a Convenience Creditor Election Form (appended to the Proposal) to the Proposal Trustee by no later than 5:00 p.m. (Toronto time) on December 11, 2020. A copy of the Convenience Creditor Election Form will also be available for download at the Proposal Trustee’s Website.

In order to be approved, the Proposal requires the affirmative vote of a majority in number and two-third in value of all proven claims of Creditors entitled to vote, who are present and voting at the Creditors’ Meeting, in accordance with the voting procedures established by the Proposal and the BIA.

The Proposal is in the Best Interests of the Company and its Stakeholders

        
The Company previously announced that it did not make the interest payments due on June 30, 2020 and September 30, 2020 pursuant to the Debentures. The Company also previously announced that Odyssey Trust Company Ltd. (“Odyssey“) commenced legal action against the Company alleging a breach of the terms of the Debentures as a result of the missed June 30, 2020 interest payment, and that Odyssey had purported to accelerate the Debentures and demanded immediate payment.

In light of the Company’s liquidity constraints, the board of directors of the Company (the “Board”) formed a special committee of the Board (the “Special Committee”) on August 17, 2020. On September 20, 2020, the Special Committee was given an expanded mandate, including to review and oversee the Company’s engagement with the Debentureholders and other strategic alternatives available to the Company.

Following the review process by the Special Committee, and given the circumstances currently facing the Company, including in connection with the previously announced legal proceedings involving the Company and its subsidiaries in Ontario and Arizona, the Special Committee and the Board have determined that the Recapitalization, including the Proposal, and the Support Agreement in connection with the Proposal, are in the best interests of the Company and its stakeholders. The Company recommends that Creditors vote in favour of the Proposal.

Settlement with Former Senior Officer

As previously disclosed on October 16, 2020 and November 5, 2020, the Company had commenced civil proceedings in the Arizona Superior Court and the Ontario Superior Court of Justice against Mark Krytiuk, the Company’s former Director, President and Chief Operating Officer (the “Legal Actions”).

The Company’s disputes with Mr. Krytiuk have now been resolved, including in respect of outstanding employment entitlements. Mr. Krytiuk has agreed to an orderly transition of his directorship and other positions and interests in Perpetual Healthcare, Inc. (“Perpetual”) to a nominee of Nabis. Nabis expects that its nominee will be appointed to the board of directors of Perpetual imminently. The Legal Actions will be discontinued on a without costs and with prejudice basis.

Forward-Looking Statements

All statements, other than statements of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The risks are without limitations: that the acquisitions will be completed by the Company or completed upon the terms disclosed; the price for cannabis and related products will remain consistent and the consumer demand remains strong; availability of financing to the Company to develop the retail locations; retention of key employees and management; changes in State and/or municipal regulations of retail operations and changes in government regulations generally. Important factors that could cause actual results to differ, materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time with the Canadian Securities Exchange, the British Columbia Securities Commission, the Ontario Securities Commission and the Alberta Securities Commission.

The Canadian Securities Exchange has neither reviewed nor approved the contents of this news release and accepts no responsibility for the adequacy or accuracy of this release.

For inquiries, please contact:

Emmanuel Paul, Chairman of the Board
[email protected]

Posted on November 23, 2020 8:33 am

Aesthetic Medical International Holdings Group Limited to Host Third Quarter 2020 Earnings Conference Call at 8:00 am ET on November 30, 2020

Shenzhen, China, Nov. 23, 2020 (GLOBE NEWSWIRE) — Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces that the Company will host its earnings conference call on Monday, November 30, 2020 at 8:00 am Eastern Time (5:00 am Pacific Time/ 9:00 pm Beijing Time) to discuss the Company’s financial results of the third quarter ended September 30, 2020.

To attend this earnings conference call, please use the information below for either dial-in access or webcast access. When prompted, please reference “Aesthetic Medical International Holdings Group Limited”

Conference Call
Date:	November 30, 2020
Time:	8:00 am ET, U.S.
International Toll Free:	United States: +1 888-346-8982 Canada: +1 855-669-9657 Mainland China: +86 400-120-1203 Hong Kong: +852 800-905-945
International:	International: +1 412-902-4272
Conference ID:	Aesthetic Medical International Holdings Group Limited

Please dial in at least 15 minutes before the commencement of the call to ensure timely participation. For those unable to participate, an audio replay of the conference call will be available from approximately one hour after the end of the live call until December 7, 2020. The dial-in for the replay is +1 877-344-7529 within the United States or +1 412-317-0088 internationally. The replay access code is 10150230.

A live and archived webcast of the call will also be available on AIH’s website at: https://ir.aihgroup.net/. Please log in at least 10 minutes prior to the conference call in order to download the applicable audio software.

About Aesthetic Medical International Holdings Group Limited

AIH, known as “Peng’ai” in China, is a leading provider of aesthetic medical services in China. AIH operates through treatment centers that spread across major cities in mainland China, and also has presence in Hong Kong and Singapore. Leveraging over 20 years of clinical experience, AIH provides one-stop aesthetic service offerings, including surgical aesthetic treatments, non-surgical aesthetic treatments, and general medical services and other aesthetic services. According to certain third party industry consultant, AIH was the third-largest private aesthetic medical services provider in China in terms of revenue in 2018. For more information regarding the Company, please visit: https://ir.aihgroup.net/.

Safe Harbor Statement

This press release contains “forward-looking statements.” These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. These risks and uncertainties and others that relate to the Company’s business and financial condition are detailed from time to time in the Company’s SEC filings, and could cause the actual results to differ materially from those contained in any forward-looking statement. These forward-looking statements are made only as of the date indicated, and the Company undertakes no obligation to update or revise the information contained in any forward-looking statements, except as required under applicable law.

Investor Relations Contact

For investor and media inquiries, please contact:

Aesthetic Medical International Holdings Group Limited

Email: [email protected]

Ascent Investor Relations LLC

Ms. Tina Xiao

Tel: (917) 609-0333

Email: [email protected]